Respiratory
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
AstraZeneca Joins The $35 Club With Cap On Inhaler Copays
The British drug maker’s move follows that of Boehringer Ingelheim earlier this month, which itself followed increasing political scrutiny on out-of-pocket costs.
InflaRx Picks Outcomes-Based Reimbursement For COVID-19 Drug
The model, more common with high-cost gene therapies, is designed to de-risk use of the drug for hospitals in the event that patients with COVID-19-related ARDS do not survive.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Vertex Aims To Shift Patients From Trikafta To Its New Triplet
Alongside its Q4 results, the group presented data showing its new cystic fibrosis triplet to be as effective as its old one, and more convenient.
10 Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are ten (plus a few extras) that have caught Scrip’s eye for one reason or another, eg, for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.
GSK Takes A Deep Breath And Drops $1bn On Aiolos
The UK firm is following in AstraZeneca’s footsteps in doing a deal for an anti-TSLP antibody, though it remains some way behind its rival.
Five Clinical Trial Misses Of 2023
The biopharma industry’s fate lies largely in its R&D success and failures. Here, Scrip looks at five clinical trial failures that got readers clicking in 2023. Some were more comprehensive than others, highlighting the nuance that can be injected into clinical data in different settings and subgroups.
Five Clinical Trial Hits Of 2023
The biopharma industry’s fate lies largely in its R&D successes and failures. Here, Scrip looks at five clinical trial successes that will shape their sponsors’ futures and got readers clicking in 2023.
Verona Tops Up Cashpile As Prospective Partners Circle
GSK is looking to do some dealmaking in the respiratory space and fellow UK firm Verona, which has just inked a $400m loan ahead of an expected US approval for its chronic obstructive pulmonary disease candidate ensifentrine, seems a perfect partner.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: first ever gene editing FDA nod; US FTC ruffles pharma’s feathers; AstraZeneca pays to play in RSV; Syndax leukemia drug makes splash at ASH; BMS bets big on Chinese ADC.
AstraZeneca Pays Big To Get Into RSV
The UK group buys its first vaccine company, Icosavax, with an eye to its platform technology.
Sanofi Tries To Win Skeptics Over To Its Immunology Masterplan
Investors balked at Sanofi plans to raise R&D spending and eat into profits, so CEO Paul Hudson and new R&D chief Houman Ashrafian need to convince doubters that its immunology focused plan will pay off.
Dupixent Heralds The Age Of Biologics In COPD
A second pivotal hit positions Sanofi and Regeneron’s antibody for approval in COPD – but other biologics are coming fast.
It’s Official: The Merck-Daiichi Deal Has The Biggest Upfront Ever
But the partners will have to avoid the pitfalls that have bedevilled several other expensive licensing deals.
Agomab Gets $100m In Fifth Largest European Venture Round This Year
But the cash will probably not be enough to prove its lead compound’s efficacy for a severe form of Crohn’s disease.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: major Q4 catalysts; Verona’s COPD contender; Alfasigma acquires Intercept; more setbacks for Keytruda/Lenvima combo; and new pressures on China IPOs.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.